AstraZeneca Phase 3 SUMIT Study of Selumetinib in Combination with Dacarbazine Did Not Meet Primary Endpoint
July 22, 2015 at 05:54 AM EDT
AstraZeneca (NYSE: AZN) today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of ...
